Meeting
2022 ASCO Annual Meeting
Impact of EGFRA289T/V mutation on relapse pattern in glioblastoma.
Authors
Fontanilles Maxime
Cancer Centre Henri Becquerel, Rouen, France
Fontanilles Maxime , Alexandra Noeuveglise , Nasrin Vasseur , Ludivine Beaussire , Florent Marguet , Romain Modzelewski , Chantal Hanzen , Cristina Alexandru , Nicolas Magne , Olivier Langlois , Frédéric Di Fiore , Florian Clatot , Sébastien Thureau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT02617745
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2046)
DOI
10.1200/JCO.2022.40.16_suppl.2046
Abstract #
2046
Poster Bd #
384
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer.
First Author: Melissa Lynne Johnson
Poster
2023 ASCO Annual Meeting
A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.
First Author: Paul James Mulholland
Poster
2021 ASCO Annual Meeting
Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma.
First Author: Yoshiki Arakawa
Poster
2020 ASCO Virtual Scientific Program
Proteomic profiling to identify therapeutics targets in glioblastoma (GBM).
First Author: Sheeno P. Thyparambil